Myocardial infarction or heart attack is
an irreversible acute medical condition, which leads to the necrosis of
heart muscles secondary to extended ischemia. Myocardial infarction
occurs when a part of heart is deprived of oxygen, which is caused due
to the blockage of one of the coronary arteries. Usually blockage is
developed due to the buildup of atherosclerotic plaque on the walls of
arteries. In most of the cases, myocardial infarctions are located in
the septal, anterior, posterior, lateral or inferior walls of the left
ventricle of the heart. Thus, lack of oxygen causes distinctive pain in
the chest and death of myocardial tissue, which leads to myocardial
infarction in humans.
In terms of geography, North America is
the largest market for myocardial infarction treatment market due to
high incidence and prevalence rate of cardiac diseases coupled with
increasing base of obese population. According to the Centers for
Disease Control and Prevention (CDC), approximately 600,000 people in
the U.S. die of heart disease annually. The organization also claims
that annually the U.S. spends around USD 108.9 billion on treatment and
management of coronary heart diseases. Moreover, according to the Heart
Foundation, by the end of 2014, approximately 920,000 people in the U.S.
will have a heart attack. Thus, this large base of heart patients is
expected to drive the market growth of myocardial infarction treatment
in this region. However, other regions such as South East Asia, Middle
East and Latin America are expected to be the prospective market in the
future. Owing to the high incidence rate of heart diseases and high
adoption rate for advanced therapeutics, these regions are expected to
be the potential market in the near future.
Overall, the myocardial infarction
treatment market is witnessing an admirable growth due to the rising
incidence rate of cardiovascular diseases and increasing base of
geriatric population. Moreover, other factors that are contributing to
the growth of this market are high incidence rate of obesity along with
chronic diseases such as diabetes, hypertension and chronic kidney
diseases. Furthermore, unhealthy lifestyle practices, excessive alcohol
consumption and use of drugs such as amphetamines and cocaine, among
population are the important risk factors for myocardial infarction;
alternatively, which would boosts the growth of myocardial infarction
treatment and management products in the near future. It has also been
estimated that, the global myocardial infarction treatment market shows
potential to be a lucrative and expanding field due the increasing
adoption rate for effective and safe treatment regimens. Expected
technological breakthroughs will generate abundant opportunities for
detecting targeted blockages, monitoring cellular response and for
determining genetic predisposition, which might alternatively drive the
growth of the myocardial infarction treatment market. However, rise in
overall healthcare expenditure, stringent regulatory policies and high
costs of clinical trials are some of the market-restraining factors that
might impede the growth of myocardial infarction treatment market in
the near future.
At present, the myocardial infarction
treatment market is a highly fragmented and established market owing to
the involvement of many recognized as well as emerging players in this
industry. However, it has been estimated that in the near future new
entrants will try to invade this industry due to the high incidence and
prevalence rate of acute myocardial infarction and other cardiovascular
diseases. Some of the major players involved in this market are Bayer
HealthCare LLC, Daiichi Sankyo, Inc., Eli Lilly and Company, Janssen
Biotech, Inc., Merck & Co. Inc., Novartis International AG and
Sanofi amongst others.
No comments:
Post a Comment